Researchers in the Burns group at Stanford designed a reaction methodology that allows for a green and inexpensive cycloaddition of amine or amide-containing unactivated olefins for the synthesis of biologically relevant cyclobutanes.
Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra
Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.
Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.
Stanford inventors have discovered that applying a hydrogel containing an inhibitor of mechanotransduction pathways on top of a skin graft reduces scarring and promotes healing after repair of traumatic injuries like severe burn wounds.